OTUD7B, SQSTM1/p62, and Antiviral Immunity

2026-10-06

The 2022 Autophagy study identifies OTUD7B as a negative regulator of antiviral immunity that connects deubiquitination, SQSTM1/p62 activation, and selective autophagic degradation of IRF3. Its central contribution is a mechanistic model in which virus-induced OTUD7B creates negative feedback on type I interferon signaling by promoting IRF3 turnover.

EdU Imaging Kits (488): Evidence & Limits

2026-10-06

EdU Imaging Kits (488) use 5-ethynyl-2'-deoxyuridine to label DNA synthesis during S phase through fluorescent click chemistry. The method supports microscopy and flow cytometry, but its signal should not be interpreted as a standalone measure of cell division, viability, or tumor progression.

Recombinant Human IL-12 in MRSA Research

2026-10-05

Recombinant Human IL-12 offers a useful immunology framework for interpreting MRSA research, but it should not be conflated with direct antibacterial agents. This article examines how IL-12 biology complements the membrane-disruption findings reported for YZ462 while defining the evidence boundaries for host-response studies.

Cy3-UTP: Evidence, Uses and Limits

2026-10-05

A source-grounded overview of Cy3-UTP, its proposed role in fluorescent RNA research, and what current evidence can—and cannot—establish.

Dimethyloxalylglycine (DMOG) Product Overview

2026-10-04

Dimethyloxalylglycine (DMOG), SKU A4506, is described by APExBIO as a research-use compound for conceptual studies of hypoxia-inducible factor stabilization and hypoxia signaling. No matched paper evidence was provided, so performance, mechanisms, and experimental outcomes are not independently assessed.

ML216 as a BLM Helicase Inhibitor: Evidence Overview

2026-10-03

ML216 is a research compound described as a selective BLM helicase inhibitor. This overview separates supplier-reported BLM evidence from a 2022 PNAS study in which ML216 was used in research on WRN dependence in mismatch-repair-deficient colorectal cancer, clarifying what the findings support, where target attribution remains uncertain, and why the evidence is not clinical validation.

STING Agonist-1: From Pathway to Translation

2026-10-02

A mechanistic and translational perspective on STING agonist-1 as a research tool for connecting innate immune signaling with IRF4-positive B-cell activation, tertiary lymphoid structures, and cancer immunotherapy research.

Fulvestrant (ICI 182,780) Research Workflow

2026-10-01

Build reproducible ERα loss-of-function assays with Fulvestrant (ICI 182,780), from concentration selection and MDM2 tracking to chemotherapy-sensitization studies. The workflow also shows how the compound can serve as a mechanistic control when estrogen signaling is examined alongside immune-cell and endoplasmic-reticulum-stress readouts.

iRGD-RBC Membranes Enhance Neuroblastoma PDT

2026-10-01

This study developed iRGD-functionalized red blood cell membrane vesicles for targeted delivery of the photosensitizer TPOR in neuroblastoma. The biomimetic carrier improved drug release, cellular uptake, apoptosis, migration inhibition, and tumor growth control compared with free TPOR, while also highlighting important translational questions about biodistribution, manufacturing, and photodynamic treatment standardization.

Cyclosporin A: From Structure to Assay Design

2026-09-30

Cyclosporin A connects cyclophilin biology, calcineurin-NFAT signaling, and mitochondrial pore regulation. This guide translates variant-level structural evidence into better assay selection, controls, and interpretation for immunology and mitochondrial research.

2-NBDG Glucose Uptake Assay Kit for HCC

2026-09-30

The 2-NBDG Glucose Uptake Assay Kit provides a rapid, non-radioactive way to connect transporter activity with sorafenib-response phenotypes in hepatocellular carcinoma models. Its single-cell fluorescence readout, PI viability control, and phloretin specificity control help separate altered glucose uptake from cell loss or nonspecific fluorescence.

FPH1: Building a Function-First Liver Platform

2026-09-29

FPH1 (BRD-6125) reframes hepatocyte expansion around function, not cell number alone. This thought-leadership article connects functional proliferation assays and iPSC-derived hepatocyte workflows with emerging, light-regulated gene therapy while clearly separating established evidence from future translational opportunities.

Transient P1 Unwinding in Adenine Riboswitch Binding

2026-09-29

Carbapenemase Gene Transmission in CREC

2026-09-28

Chen et al. examined carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, combining gene detection, plasmid-transfer experiments, susceptibility testing, and strain fingerprinting. The study shows that blaNDM-1 was frequently plasmid-associated and transferable, supporting a surveillance strategy that evaluates resistance genes, mobile elements, phenotype, and clonality together.

Farnesylation-Driven KRAS Condensates in Colon Cancer

2026-09-28

The study proposes that farnesylation at KRAS C185 promotes cytoplasmic condensates that cluster RCE1, support KRAS processing and membrane localization, and amplify tumor-promoting signaling in colon cancer. It also reports that statins, particularly pitavastatin, disrupt this process and can improve response to KRAS G12C inhibition, suggesting a combination strategy that merits further validation.